Reaching for the Holy Grail in Myelofibrosis With Imetelstat Combinations | Blood Cancers Today
In an exclusive interview with Blood Cancers Today, John Mascarenhas, MD discussed the development of the imetelstat for the treatment of myelofibrosis.
Related Articles
HFSA Heart Failure Patient Education Modules | HFSA
This series of educational modules is designed to help patients learn to live successfully with heart failure. The advice in the modules can help heart…
Cardiovascular Considerations During Cancer Therapy: Gaps in Evidence and JACC: CardioOncology Expert Panel Recommendations
AbstractThe administration of certain cancer therapies can be associated with the development of cardiovascular toxicity or complications. This spectrum of toxicities is broad and requires…
ACC/AHA/ASE/HFSA/HRS/SCAI/SCCT/SCMR 2025 Appropriate Use Criteria for Implantable Cardioverter-Defibrillators, Cardiac Resynchronization Therapy, and Pacing:
American College of Cardiology Representative. American College of Cardiology Representative. American College of Cardiology Representative. Heart Failure Society of America Representative. American College of Cardiology…
Episode 405: What Can You Learn from Genetic Testing in 2025?
Podcast Episode · Heart Doc VIP with Dr. Joel Kahn · 01/14/2025 · 26m
IDH-1 Mutation Linked to Autoimmune Rheumatoid Disease in MDS | Blood Cancers Today
A recent study showed that patients with MDS and concomitant autoimmune rheumatoid diseases (AIRD) showed an increased prevalence of IDH-1 somatic mutations.
Tongue Squamous Cell Carcinoma With Cardiac Metastases:
AbstractA 60-year-old man with squamous cell carcinoma of the tongue had atypical chest pain and mild troponin elevation. No significant electrocardiogram changes or arrhythmias were…
LLS | How Patients Really Feel About Artificial Intelligence in Healthcare
Artificial intelligence will soon play an even bigger role in healthcare. Here’s what patients are worried about and how to alleviate some of the fear.
Journal of the American College of Cardiology: Vol 85, No 2
Harlan M. Krumholz and Theresa McDonagh JACC. 2025 Jan, 85 (2) 103–105. JACC. 2025 Jan, 85 (2) 106–116. JACC. 2025 Jan, 85 (2) 117–119. JACC.…
JACC | MasterClass | FINEARTS
In the latest in the JACC Masterclass series, Harlan M. Krumholz, MD, SM, Editor-in-Chief of JACC, is joined by Scott Solomon, MD, PhD, discussing the…
Finerenone and Kidney Outcomes in Patients with Heart Failure: The FINEARTS-HF Trial:
AbstractBackgroundFinerenone has kidney protective effects in patients with chronic kidney disease (CKD) with type 2 diabetes, but effects on kidney outcomes in patients with heart…